Editas Medicine Inc. (NASDAQ:EDIT) was down 4.3% during mid-day trading on Wednesday . The stock traded as low as $18.87 and last traded at $19.09, with a volume of 176,522 shares traded. The stock had previously closed at $19.94.

Several equities research analysts have issued reports on EDIT shares. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a report on Monday. Jefferies Group started coverage on Editas Medicine in a report on Thursday, June 2nd. They issued a “hold” rating and a $35.00 price target for the company. Vetr upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target for the company in a report on Monday, May 9th. Finally, Cowen and Company restated a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Editas Medicine presently has an average rating of “Hold” and an average price target of $33.50.

The stock’s market capitalization is $623.11 million. The stock has a 50-day moving average price of $24.33 and a 200-day moving average price of $29.34.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.54) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.54). Analysts anticipate that Editas Medicine Inc. will post ($2.59) EPS for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.